



Ref: FOIA Reference 2024/25-607

Date: 13th December 2024

Email foi@uhnm.nhs.uk

Dear Sir/Madam

I am writing to acknowledge receipt of your email dated 29th November 2024 requesting information under the Freedom of Information Act (2000) regarding non-small cell lung cancer

Q1 Question One:

How many early-stage (non-metastatic or Stages 2-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

- **Atezolizumab (Tecentriq)**
- **Durvalumab (Imfinzi)**
- **Nivolumab (Opdivo)**
- **Pembrolizumab (Keytruda)**
- **Chemotherapy**
- **Radiotherapy**
- **Chemotherapy AND Radiotherapy**

A1 I can neither confirm nor deny whether the information you have requested is held by the Trust in its entirety. This is because the information requested in this question is not held centrally but may be recorded in health records. In order to confirm whether this information is held we would therefore have to individually access all health records within the Trust and extract the information where it is present. We therefore estimate that complying with your request is exempt under section 12 of the FOI Act: *cost of compliance is excessive*. The section 12 exemption applies when it is estimated a request will take in excess of 18 hours to complete. We estimate that accessing and reviewing all health records and then extracting relevant information would take longer than the 18 hours allowed for.

In addition to the section 12 exemption the Trust is also applying section 14 (1) exemption: *oppressive burden on the authority*

Please note that the below figures include all patients. Staging data is not available without accessing individual patient notes.

Atezolizumab (Tecentriq)	16
Durvalumab (Imfinzi)	5

Nivolumab (Opdivo)	8
Pembrolizumab (Keytruda)	37
Chemotherapy	98
Radiotherapy	15
Chemotherapy AND Radiotherapy	0

Q2 Question Two:

How many patients has your Trust treated in total in the past 3 months for

- Stage 2 Non-Small Cell Lung Cancer
- Stage 3 Non-Small Cell Lung Cancer

A2 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information*. However, as the Trust is committed to openness and transparency, we can band the numbers as being <5. *This exemption is an absolute exemption and therefore no consideration of the public interest test is needed.*

Information is for where staging has been completed and where a diagnosis has been recorded from 01/04/2024 onwards.

Stage 2 Non-Small Cell Lung Cancer	<5
Stage 3 Non-Small Cell Lung Cancer	41

Q3 Question Three:

How many patients who received Pembrolizumab for Non-Small Cell Lung Cancer (NSCLC) (any stage) in the last 3 months, received:

Pembrolizumab Monotherapy

1. Treatment every 3 weeks (200mg, Q3W)
2. Treatment every 6 weeks (400mg, Q6W)

Pembrolizumab in combination with chemotherapy

1. Treatment every 3 weeks (200mg, Q3W)
2. Treatment every 6 weeks (400mg, Q6W)

A3 Please see below.

Pembrolizumab Monotherapy		
1.	Treatment every 3 weeks (200mg, Q3W)	12
2.	Treatment every 6 weeks (400mg, Q6W)	5
Pembrolizumab in combination with chemotherapy		
1.	Treatment every 3 weeks (200mg, Q3W)	20
2.	Treatment every 6 weeks (400mg, Q6W)	0

*Please note that any individuals identified do not give consent for their personal data to be processed for the purposes of direct marketing.

UHNM NHS Trust is a public sector body and governed by EU law. FOI requestors should note that any new Trust requirements over the EU threshold will be subject to these regulations and will be advertised for open competition accordingly.

Where the Trust owns the copyright in information provided, you may re-use the information in line with the conditions set out in the Open Government Licence v3 which is available at <http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/>. Where information was created by third parties, you should contact them directly for permission to re-use the information.

An anonymised copy of this request can be found on the Trust's disclosure log, please note that all requests can be found at the following link: <http://www.uhnm.nhs.uk/aboutus/Statutory-Policies-and-Procedures/Pages/Freedom-of-Information-Disclosure-Log.aspx>

This letter confirms the completion of this request. A log of this request and a copy of this letter will be held by the Trust.

If you have any queries related to the response provided please in the first instance contact my office.

Should you have a complaint about the response or the handling of your request, please also contact my office to request a review of this. If having exhausted the Trust's FOIA complaints process you are still not satisfied, you are entitled to approach the Information Commissioner's Office (ICO) and request an assessment of the manner in which the Trust has managed your request.

The Information Commissioner may be contacted at:

Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF or via www.ico.org.uk.

Yours,



Leah Carlisle
Head of Data, Security & Protection and Health Records
Data Protection Officer